Division of Pfizer Inc.
Latest From Medivation Inc.
Axovant was Roivant's star and the first test of its risk-reducing strategy, but the company will attempt to move its spotlight to other assets at an R&D day on July 10. Ahead of the event, Roivant announced a reorganization to strengthen its subsidiaries and accelerate the creation of new ones.
Pfizer's Three-Pronged Oncology Strategy Includes Expanding Ibrance, Xtandi, Developing Blockbuster Combos
Xtandi use in early prostate cancer, lorlatinib as second-line treatment for non-small cell lung cancer and dacomitinib for first-line NSCLC have upcoming user fee dates.
The competitive dynamics in the pharmaceutical sector appear to be intensifying, with second- and third-to-market drugs reaching the market faster behind first-in-class drugs. That's putting more pressure on new drug launches and impacting drug pricing and rebating strategies.
AbbVie announced positive data from the first of two pivotal Phase III studies testing the GnRH receptor antagonist, but Allergan and Myovant are among the companies also looking to bring new drugs to market.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
David T Hung, MD, Pres. & CEO
Jennifer Jarrett, CFO
Joseph Lobacki, Chief Commercial Officer
Marion McCourt, COO
- Contact Info
Phone: (415) 543-3470
525 Market St.
San Francisco, CA 94105
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.